{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:33:43Z","timestamp":1777923223243,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      Levonadifloxacin (IV) and alalevonadifloxacin (oral) are novel broad-spectrum anti-methicillin-resistant\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                      ) agents based on novel benzoquinolizine core. Both are recently approved in India for the treatment of acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteremia. The present investigation reports the findings from preclinical pharmacokinetic (PK) studies that support the development of levonadifloxacin as a treatment option for bone and joint infections (BJIs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>PK profiles of levonadifloxacin were obtained in serum, and\/or various anatomical segments of femoral bone such as whole bone (WB), hard bone (HB), and bone marrow (BM) following subcutaneous administration of levonadifloxacin single doses at 50, 100, 200, and 400 mg\/kg, as well as multiple doses at 200 mg\/kg (BID (two times a day), 6 hours apart) for 5 days in Wistar rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The distribution of levonadifloxacin in bone was rapid, and the extent of distribution (B\/S ratio; bone-to-serum area under the concentration\u2013time curve ratio) was nearly comparable across bone segments. In single-dosage PK studies, the mean B\/S ratio in WB, HB, and BM was 0.40, 0.33, and 0.34, respectively; however, in 5 days\u2019 repeated dose studies, it increased to 1.01, 1.14, and 0.61, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>On the basis of bone PK data in Wistar rat and ever-growing clinical experience in terms of safety and efficacy, levonadifloxacin has the potential to offer a well-differentiated therapy for the treatment of BJIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/mdr.2024.0118","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T05:07:46Z","timestamp":1727932066000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum Pharmacokinetics and Bone Penetration of Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin in Wistar Rats"],"prefix":"10.1177","volume":"30","author":[{"given":"Rajesh","family":"Chavan","sequence":"first","affiliation":[{"name":"New Drug Discovery Research, Wockhardt Research Centre, Chhatrapati Sambhajinagar, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Zope","sequence":"additional","affiliation":[{"name":"New Drug Discovery Research, Wockhardt Research Centre, Chhatrapati Sambhajinagar, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avinash","family":"Karade","sequence":"additional","affiliation":[{"name":"New Drug Discovery Research, Wockhardt Research Centre, Chhatrapati Sambhajinagar, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manohar","family":"Nandanwar","sequence":"additional","affiliation":[{"name":"New Drug Discovery Research, Wockhardt Research Centre, Chhatrapati Sambhajinagar, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Bhagwat","sequence":"additional","affiliation":[{"name":"New Drug Discovery Research, Wockhardt Research Centre, Chhatrapati Sambhajinagar, India."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"6","key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkh191","article-title":"Antibiotic treatment of gram-positive bone and joint infections","volume":"53","author":"Darley ESR","year":"2004","unstructured":"Darley ESR, , MacGowan AP. Antibiotic treatment of gram-positive bone and joint infections. J Antimicrob Chemother, 2004; 53(6):928\u2013935.","journal-title":"J Antimicrob Chemother"},{"issue":"40","key":"e_1_3_4_3_2","first-page":"2265","article-title":"\u201cDiffusion osseuse des antibiotiques\u201d [Diffusion in bone tissue of antibiotics]","volume":"28","author":"Boselli E","year":"1999","unstructured":"Boselli E, , Allaouchiche B. \u201cDiffusion osseuse des antibiotiques\u201d [Diffusion in bone tissue of antibiotics]. Presse Med, 1999; 28(40):2265\u20132276.","journal-title":"Presse Med"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00134-14"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704033361406"},{"issue":"1","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2958.1993.tb01101.x","article-title":"A collagen receptor on staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage","volume":"7","author":"Switalski LM","year":"1993","unstructured":"Switalski LM, , Patti JM, , Butcher W, et al. A collagen receptor on staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage. Molecular Microbiology, 1993; 7(1):99\u2013107.","journal-title":"Molecular Microbiology"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1384"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaa114"},{"issue":"1","key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the infectious diseases society of America","volume":"56","author":"Osmon DR","year":"2012","unstructured":"Osmon DR, , Berbari EF, , Berendt AR, et al. Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the infectious diseases society of America. Clinical Infectious Diseases, 2012; 56(1):e1\u2013e25.","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"e00420","DOI":"10.1002\/prp2.420","article-title":"Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations","volume":"6","author":"Monteiro JF","year":"2018","unstructured":"Monteiro JF, , Hahn SR, , Gon\u00e7alves J, et al. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect, 2018; 6(4):e00420.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant staphylococcus aureus agent levonadifloxacin: Therapeutic role in nosocomial and community infections","volume":"37","author":"Bakthavatchalam YD","year":"2019","unstructured":"Bakthavatchalam YD, , Rao SV, , Isaac B, et al. A comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant staphylococcus aureus agent levonadifloxacin: Therapeutic role in nosocomial and community infections. Indian J Med Microbiol, 2019; 37(4):478\u2013487.","journal-title":"Indian J Med Microbiol"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00455-10"},{"issue":"8","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1128\/AAC.00735-16","article-title":"New insight into daptomycin bioavailability and localization in staphylococcus aureus biofilms by dynamic fluorescence imaging","volume":"60","author":"Boudjemaa R","year":"2016","unstructured":"Boudjemaa R, , Briandet R, , Revest M, et al. New insight into daptomycin bioavailability and localization in staphylococcus aureus biofilms by dynamic fluorescence imaging. Antimicrob Agents Chemother, 2016; 60(8):4983\u20134990.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106712"},{"issue":"10","key":"e_1_3_4_15_2","first-page":"e10890","article-title":"Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant staphylococcus aureus","volume":"12","author":"Sharma S","year":"2020","unstructured":"Sharma S, , Syal A, , Gupta M, et al. Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant staphylococcus aureus. Cureus, 2020; 12(10):e10890.","journal-title":"Cureus"},{"issue":"1","key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/antibiotics13010004","article-title":"A review of the clinical utilization of oral antibacterial therapy in the treatment of bone infections in adults","volume":"13","author":"Haddad N","year":"2023","unstructured":"Haddad N, , Ajaz J, , Mansour L, et al. A review of the clinical utilization of oral antibacterial therapy in the treatment of bone infections in adults. Antibiotics (Basel), 2023; 13(1):4.","journal-title":"Antibiotics (Basel)"},{"key":"e_1_3_4_17_2","first-page":"2668199","article-title":"Meeting the unmet need in the management of MDR gram-positive infections with oral bactericidal agent levonadifloxacin","volume":"2022","author":"Mehta Y","year":"2022","unstructured":"Mehta Y, , Mishra KC, , Paliwal Y, et al. Meeting the unmet need in the management of MDR gram-positive infections with oral bactericidal agent levonadifloxacin. Crit Care Res Pract, 2022; 2022:2668199.","journal-title":"Crit Care Res Pract"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijmmb.2022.11.005","article-title":"India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care","volume":"41","author":"Veeraraghavan B","year":"2023","unstructured":"Veeraraghavan B, , Bakthavatchalam YD, , Manesh A, et al. Drug Discovery group, Wockhardt. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care. Indian J Med Microbiol, 2023; 41:71\u201380.","journal-title":"Indian J Med Microbiol"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: Review of current evidence","volume":"13","author":"Bhagwat SS","year":"2019","unstructured":"Bhagwat SS, , Nandanwar M, , Kansagara A, et al. Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: Review of current evidence. Drug Des Devel Ther, 2019; 13:4351\u20134365.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1093\/clinids\/10.Supplement_1.S179","article-title":"New quinolones in the treatment of joint and bone infections","volume":"10","author":"Desplaces N","year":"1988","unstructured":"Desplaces N, , Acar JF. New quinolones in the treatment of joint and bone infections. Rev Infect Dis, 1988; 10(Suppl 1):S179\u2013S183.","journal-title":"Rev Infect Dis"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3338-3342.2004"},{"issue":"5","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the hershey medical center","volume":"52","author":"Bozdogan B","year":"2003","unstructured":"Bozdogan B, , Esel D, , Whitener C, et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the hershey medical center. J Antimicrob Chemother, 2003; 52(5):864\u2013868.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_4_23_2","article-title":"Comparative activity of WCK 771 against S. Aureus with raised vancomycin and daptomycin mics and other resistotypes","author":"McHgee P","year":"2006","unstructured":"McHgee P, , Appelbaum PC. Comparative activity of WCK 771 against S. Aureus with raised vancomycin and daptomycin mics and other resistotypes. In: Abstract F1-2129. Presented at 46th Intersci. Conf. Antimicrob. Agents Chemother American Society for Microbiology: Washington, DC; 2006.","journal-title":"Abstract F1-2129. Presented at 46th Intersci. Conf. Antimicrob"},{"key":"e_1_3_4_24_2","article-title":"In vitro activity of WCK 771, a benzoquinolizine fluoroquinolone (levonadifloxacin) when tested against contemporary gram-positive and-negative bacteria from a global surveillance program","author":"Flamm RK","year":"2016","unstructured":"Flamm RK, , Farrell DJ, , Sader HS, et al. In vitro activity of WCK 771, a benzoquinolizine fluoroquinolone (levonadifloxacin) when tested against contemporary gram-positive and-negative bacteria from a global surveillance program. In: Sunday-456. Presented at 1st annual American Society for Microbiology General Meeting (MICROBE); 2016; Boston, Massachusetts.","journal-title":"Sunday-456. Presented at 1st annual American Society for Microbiology General Meeting (MICROBE)"},{"key":"e_1_3_4_25_2","article-title":"In vitro activity of WCk771, a new benzoquinolizine quinolone in development, against key bacterial groups from the USA and Europe","author":"Hackel M","year":"2015","unstructured":"Hackel M, , Bhagwat S, , Kanade H, et al. In vitro activity of WCk771, a new benzoquinolizine quinolone in development, against key bacterial groups from the USA and Europe. Abstr F-1196. 55th ICAAC (Intersci Conf Antimicrob Agents Chemother); San Diego, CA American Society for Microbiology, Washington, DC; 2015.","journal-title":"Abstr F-1196. 55th ICAAC (Intersci Conf Antimicrob Agents Chemother)"},{"issue":"11","key":"e_1_3_4_26_2","article-title":"In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms","volume":"62","author":"Xue G","year":"2018","unstructured":"Xue G, , Crabb DM, , Xiao L, et al. In vitro activities of the benzoquinolizine fluoroquinolone levonadifloxacin (WCK 771) and other antimicrobial agents against mycoplasmas and ureaplasmas in humans, including isolates with defined resistance mechanisms. Antimicrob Agents Chemother, 2018; 62(11):e01348\u201318.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"e_1_3_4_27_2","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01048-19","article-title":"In vitro activity of levonadifloxacin (WCK 771) against chlamydia pneumoniae","volume":"63","author":"Kohlhoff S","year":"2019","unstructured":"Kohlhoff S, , Huerta N, , Hammerschlag M. In vitro activity of levonadifloxacin (WCK 771) against chlamydia pneumoniae. Antimicrob Agents Chemother, 2019; 63(8):e01048\u201319.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1128\/AAC.48.8.3188-3192.2004","article-title":"Anti-anaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents","volume":"48","author":"Peric M","year":"2004","unstructured":"Peric M, , Jacobs MR, , Appelbaum PC. Anti-anaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. Antimicrob Agents Chemother, 2004; 48(8):3188\u20133192.","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_29_2","article-title":"In vitro activity of WCK 771, a broad-spectrum anti-MRSA benzoquinolizine subclass of quinolone against five biodefense bacterial pathogens","author":"Heine HS","year":"2015","unstructured":"Heine HS, , Demons ST, , Miller LL, et al. In vitro activity of WCK 771, a broad-spectrum anti-MRSA benzoquinolizine subclass of quinolone against five biodefense bacterial pathogens. Abstract F-1188. Presented at 55th Intersci Conf Antimicrob Agents Chemother (ICAAC); 2015; San Diego.","journal-title":"Abstract F-1188. Presented at 55th Intersci Conf Antimicrob Agents Chemother (ICAAC)"},{"key":"e_1_3_4_30_2","first-page":"21","volume-title":"From Microbiology to Diagnostics and Treatment","author":"Landersdorfer C","year":"2015","unstructured":"Landersdorfer C, , Bulitta J, , Sorgel F. Pharmacokinetics and pharmacodynamics of antibiotics in bone, in bone and joint infections. In: From Microbiology to Diagnostics and Treatment. (Zimmerli W., editor) John Wiley & Sons: Chichester UK, 2015, pp. 21\u201337."},{"key":"e_1_3_4_31_2","article-title":"In vitro activity of levonadifloxacin against legionella pneumophilia, abstract P0620","author":"Dubois J","year":"2018","unstructured":"Dubois J, , Dubois M. In vitro activity of levonadifloxacin against legionella pneumophilia, abstract P0620. Presented at 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID); 2018; Spain.","journal-title":"Presented at 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)"},{"issue":"8","key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1099\/jmm.0.000999","article-title":"In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms","volume":"68","author":"Tellis M","year":"2019","unstructured":"Tellis M, , Joseph J, , Khande H, et al. In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms. J Med Microbiol, 2019; 68(8):1129\u20131136.","journal-title":"J Med Microbiol"},{"key":"e_1_3_4_33_2","article-title":"The impact of NorA mediated efflux on in vitro and in\u00a0vivo anti-Staphylococcal efficacy of an investigational fluoroquinolone (FQ) WCK 771 A and other FQs","author":"Gupte SV","year":"2001","unstructured":"Gupte SV, , Patel MV, , Agarwal SK, et al. The impact of NorA mediated efflux on in vitro and in\u00a0vivo anti-Staphylococcal efficacy of an investigational fluoroquinolone (FQ) WCK 771 A and other FQs. Abstract F-537. 41st Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2001; Chicago.","journal-title":"Abstract F-537. 41st Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC)"},{"key":"e_1_3_4_34_2","article-title":"WCK 771 A-an investigational anti-MRSA fluoroquinoone (FQ) with potent concentration independent cidal action and an unusual ability to kill slow growing Staphylococci","author":"Upadhyay DJ","year":"2001","unstructured":"Upadhyay DJ, , Patel MV, , Gupte SK, et al. WCK 771 A-an investigational anti-MRSA fluoroquinoone (FQ) with potent concentration independent cidal action and an unusual ability to kill slow growing Staphylococci. Abstract F-534. Presented at ICAAC; 2001; Chicago.","journal-title":"Abstract F-534. Presented at ICAAC"},{"key":"e_1_3_4_35_2","article-title":"WCK 771- an investigational FQ with high intravenous tolerability","author":"Patel M","year":"2003","unstructured":"Patel M, , Gupte S, , Shetty N, et al. WCK 771- an investigational FQ with high intravenous tolerability. Abstract F-431, Presented at 43rd Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003; Chicago.","journal-title":"Abstract F-431, Presented at 43rd Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC)"},{"key":"e_1_3_4_36_2","article-title":"Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK 2349","author":"Chugh R","year":"2016","unstructured":"Chugh R, , Lakdavala F, , Bhatia A. Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK 2349. Abstract P1268. 26th Eur congr clin microbial infect dis, Amsterdam, Netherlands. European Society of Clinical Microbiology and Infectious Diseases: Basel, Switzerland; 2016.","journal-title":"Abstract P1268. 26th Eur congr clin microbial infect dis, Amsterdam, Netherlands"},{"key":"e_1_3_4_37_2","article-title":"Pharmacokinetics of intravenous WCK 771 in healthy US adults","author":"Mehrotra S","year":"2015","unstructured":"Mehrotra S, , Ivaturi V, , Gobburu J, et al. Pharmacokinetics of intravenous WCK 771 in healthy US adults. Abstract A-031, Presented at 55th ICAAC; 2015.","journal-title":"Abstract A-031, Presented at 55th ICAAC"},{"key":"e_1_3_4_38_2","article-title":"Food effect and absolute bioavailability study of WCK 2349 and WCK 771 in healthy adult human volunteer in US","author":"Chugh R","year":"2015","unstructured":"Chugh R, , Lakdavala F, , Bhagwat S, et al. Food effect and absolute bioavailability study of WCK 2349 and WCK 771 in healthy adult human volunteer in US. Abstract A-039. Presented at 55th ICAAC; 2015.","journal-title":"Abstract A-039. Presented at 55th ICAAC"},{"key":"e_1_3_4_39_2","article-title":"Single-center evaluation of the pharmacokinetics and safety of the novel fluoroquinolone WCK 2349 in hepatic impairment","author":"Preston RA","year":"2016","unstructured":"Preston RA, , Chugh R, , Mastim M, et al. Single-center evaluation of the pharmacokinetics and safety of the novel fluoroquinolone WCK 2349 in hepatic impairment. Abstract P1270. Presented 26th Eur Congr Clin Microbial Infect Dis, Amsterdam, Netherlands; 2016.","journal-title":"Abstract P1270. Presented 26th Eur Congr Clin Microbial Infect Dis"},{"issue":"3","key":"e_1_3_4_40_2","doi-asserted-by":"crossref","first-page":"e02297","DOI":"10.1128\/AAC.02297-17","article-title":"Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects","volume":"62","author":"Rodvold KA","year":"2018","unstructured":"Rodvold KA, , Gotfried MH, , Chugh R, et al. Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects. Antimicrob Agents Chemother, 2018; 62(3):e02297\u2013e02317.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2024.0118","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0118","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2024.0118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:41:46Z","timestamp":1777668106000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2024.0118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1089\/mdr.2024.0118"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2024.0118","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}